Clinical Trial Update: Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating low-dose involved-field radiotherapy plus immunochemotherapy for esophageal squamous cell carcinoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Snippet

Sponsor: Sichuan University | Conditions: Esophageal Squamous Cell Carcinoma (ESCC), Immunotherapy | Phase 2 | Status: RECRUITING